CAS: 114482-86-9; 5,6-Dihydroxy-2-Phenyl-7-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)Methyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-4H-Chromen-4-One
该化合物是来自Baicelein的氟化物胶质,一种在各种植物中发现的化合物,特别是Scutsellaria baicens的根部,其特点是,在Baicalein结构的7处,该物质在氢氧基组中附着的两种葡萄糖糖糖质,其特征是,它具有一系列生物活动,包括抗氧化剂,抗炎和潜在的抗癌特性,因此它具有药物研究的兴趣.该化合物由于具有玻璃基质性质,通常在水中溶解,这与其对丙酮的对口相比,增加了其生物利用率.Baicalein 7-O-diglucoside经常被研究其对各种细胞路径的影响及其在传统医学中的潜在治疗应用.其稳定性和再活性可能受到诸如pH和温度等因素的影响,这些因素是实验室和工业环境中的重要考虑因素.总的来说,该化合物在天然产品化学和药剂研究中具有重大的兴趣.
- 英文名称5,6-Dihydroxy-2-Phenyl-7-(((2S,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-Trihydroxy-6-(Hydroxymethyl)Tetrahydro-2H-Pyran-2-yl)Oxy)Methyl)Tetrahydro-2H-Pyran-2-yl)Oxy)-4H-Chromen-4-One
- 中文名称木蝴蝶苷B
- IUPAC名称5,6-dihydroxy-2-phenyl-7-(((2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-((((2R,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)tetrahydro-2H-pyran-2-yl)oxy)methyl)tetrahydro-2H-pyran-2-yl)oxy)-4H-chromen-4-one
- 其它别名Baicalein7-O-b-gentiobioside; Baicalein-7-O-diglucoside
- CAS编号114482-86-9
- MFCD编号:MFCD22125002
- EINECS号:109-955-9
- 分子式:C27H30O15分子量:594.52
- 产品CID: 178494
- 产品分类生物化工 → 提取物
物理性质
MSDS等安全信息
欧盟法规
C&L通报合成工艺路线路线简述
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Lu R, He Z, Zhang W, Wang Y, Cheng P, Lv Z, Yuan X, Guo F, You H, Chen AM, Hu W. Oroxin B alleviates osteoarthritis through anti-inflammation and inhibition of PI3K/AKT/mTOR signaling pathway and enhancement of autophagy. Front Endocrinol (Lausanne). 2022 Dec 1;13:1060721. doi: 10.3389/fendo.2022.1060721.
2: Huang Y, Wang C, Wang M, Xiong T, Song X, Sun W, Li J. Oroxin B improves metabolic-associated fatty liver disease by alleviating gut microbiota dysbiosis in a high-fat diet-induced rat model. Eur J Pharmacol. 2023 Jul 15;951:175788. doi: 10.1016/j.ejphar.2023.175788. Epub 2023 May 12.
15:4811-4825. doi: 10.2147/DDDT.S328238.
合成参考文献
参考文献:10.1016/j.taap.2015.07.026
摘要:Yang P, Fu S, Cao Z, Liao H, Huo Z, Pan Y, Zhang G, Gao A, Zhou Q. Oroxin B selectively induces tumor-suppressive ER stress and concurrently inhibits tumor-adaptive ER stress in B-lymphoma cells for effective anti-lymphoma therapy. Toxicol Appl Pharmacol. 2015 Oct 15;288(2):269–79. doi: 10.1016/j.taap.2015.07.026.
📝 需求与反馈
尽可能描述清楚需求与问题信息
